We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+15.94%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$732M
AUM Growth
-$316M
Cap. Flow
-$376M
Cap. Flow %
-51.38%
Top 10 Hldgs %
46.9%
Holding
119
New
21
Increased
21
Reduced
25
Closed
28

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$26M
2
INSM icon
Insmed
INSM
+$25.6M
3
TRVI icon
Trevi Therapeutics
TRVI
+$7.99M
4
ELVN icon
Enliven Therapeutics
ELVN
+$7.57M
5
VTYX
Ventyx Biosciences
VTYX
+$7.33M

Top Sells

Rank Stock Value
1
APGE icon
Apogee Therapeutics
APGE
+$17.5M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$16.8M
3
MRUS
Merus
MRUS
+$11.8M
4
CNTA
Centessa Pharmaceuticals
CNTA
+$8.19M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$7.44M

Sector Composition

Rank Sector Weight
1 Healthcare 87.76%
2 Financials 0.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TSHA icon
76
Taysha Gene Therapies
TSHA
$1.6B
$462K 0.06%
+200,000
New +$435K
CNTX icon
77
Context Therapeutics
CNTX
$56.6M
$339K 0.05%
518,025
-142,564
-22% -$103K
ENGN icon
78
enGene Therapeutics
ENGN
$125M
$280K 0.04%
+77,000
New +$289K
RPTX
79
DELISTED
Repare Therapeutics
RPTX
$278K 0.04%
200,000
– –
ZURA icon
80
Zura Bio
ZURA
$500M
$235K 0.03%
223,335
– –
OVID icon
81
Ovid Therapeutics
OVID
$431M
$220K 0.03%
667,516
– –
RADX
82
Radiopharm Theranostics
RADX
$33.7M
$166K 0.02%
35,635
-28,965
-45% -$130K
APGE icon
83
PUT
Apogee Therapeutics
APGE
$10.1B
$109K 0.01%
+2,500
New +$95.1K
ADGM
84
Adagio Medical Holdings
ADGM
$11.3M
$108K 0.01%
80,000
-133,235
-62% -$152K
QTTB icon
85
Q32 Bio
QTTB
$346M
$41.4K 0.01%
27,777
– –
ABUS icon
86
CALL
Arbutus Biopharma
ABUS
$871M
$28.7K ﹤0.01%
+9,300
New +$30.9K
RCKTW icon
87
Rocket Pharmaceuticals Warrant
RCKTW
$320K
$2.16K ﹤0.01%
75,000
– –
IMTXW
88
DELISTED
Immatics N.V. Warrants
IMTXW
$112 ﹤0.01%
187,204
– –
ALLK
89
DELISTED
Allakos
ALLK
– –
-250,000
Closed -$56.9K
ALNY icon
90
CALL
Alnylam Pharmaceuticals
ALNY
$36.4B
– –
-55,000
Closed -$14.9M
BDTX icon
91
Black Diamond Therapeutics
BDTX
$104M
– –
-250,000
Closed -$388K
CMPX icon
92
Compass Therapeutics
CMPX
$364M
– –
-130,807
Closed -$249K
CMPX icon
93
PUT
Compass Therapeutics
CMPX
$364M
– –
-1,330,700
Closed -$2.53M
CORT icon
94
CALL
Corcept Therapeutics
CORT
$9.83B
– –
-70,000
Closed -$8M
ETNB
95
DELISTED
89bio
ETNB
– –
-175,000
Closed -$1.27M
EWTX icon
96
PUT
Edgewise Therapeutics
EWTX
$4.18B
– –
-200,000
Closed -$4.4M
IBRX icon
97
PUT
ImmunityBio
IBRX
$7.86B
– –
-1,025,000
Closed -$3.09M
IMVT icon
98
Immunovant
IMVT
$8.2B
– –
-430,000
Closed -$7.35M
IWM icon
99
PUT
iShares Russell 2000 ETF
IWM
$81.2B
– –
-300,000
Closed -$59.8M
KYMR icon
100
Kymera Therapeutics
KYMR
$9.14B
– –
-100,000
Closed -$2.74M
1 2 3
4
5

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
MWA
Midland Wealth Advisors Effingham, Illinois $1.94B AUM 14.31% 1-Year Est. Return
AF
Advisornet Financial Minnetonka, Minnesota $1.93B AUM 18.43% 1-Year Est. Return
NFG
Nations Financial Group Cedar Rapids, Iowa $1.94B AUM 25.76% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM

Affinity Asset Advisors's Q2 2025 Portfolio in Review

As of Q2 2025, Affinity Asset Advisors held 119 positions worth $732M, down 30% from $1.05B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Affinity Asset Advisors withdrew a net $376M in Q2 2025, closing 28 positions and reducing 25 holdings. Its most notable exit was State Street SPDR S&P 500 ETF Trust, an estimated $16.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 55% a quarter earlier, followed by Financials.

Against the trend, Affinity Asset Advisors opened a new position in Blueprint Medicines worth $32M.

  • Affinity Asset Advisors's largest Q2 2025 buy was Blueprint Medicines: 250,000 shares worth $32M.
  • Affinity Asset Advisors added most to Insmed in Q2 2025, an estimated $25.6M increase.
  • Affinity Asset Advisors's biggest Q2 2025 reduction was Apogee Therapeutics, cutting an estimated $17.5M.
  • Affinity Asset Advisors fully exited State Street SPDR S&P 500 ETF Trust in Q2 2025, selling an estimated $16.8M.
  • Affinity Asset Advisors's ten largest holdings make up 47% of its $732M portfolio in Q2 2025.
  • Affinity Asset Advisors opened 21 new positions and closed 28 in Q2 2025.
  • Affinity Asset Advisors's portfolio value fell 30% quarter-over-quarter to $732M.

Based on Affinity Asset Advisors's 13F filing for Q2 2025, filed 13 Aug 2025.